Development of a Novel Engineered Tendon Graft to Assist in Repair of Rotator Cuff Injuries
开发新型工程肌腱移植物以协助修复肩袖损伤
基本信息
- 批准号:10697147
- 负责人:
- 金额:$ 94.33万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-07-01 至 2025-05-31
- 项目状态:未结题
- 来源:
- 关键词:AddressAllogenicAnimalsArthritisBiologicalBiomechanicsCapitalCellsCharacteristicsCicatrixClinicClinicalClinical TrialsCollagenCommunitiesDNADataDevelopmentDevicesEngineeringFailureFibrocartilagesFundingGoalsHistologicHistologyHumanInjuryInvestmentsLaboratoriesLifeMarketingMechanicsMethodologyMethodsMichiganModulusNatural regenerationOperative Surgical ProceduresOrthopedicsOutcomePatient-Focused OutcomesPatientsPhasePhase I Clinical TrialsPhysiologicalProceduresProductionPropertyProtocols documentationQualifyingRecoveryRegenerative MedicineRegenerative capacityResearchResearch PersonnelRiskRotator CuffSheepSiteSmall Business Innovation Research GrantSourceSterilitySurgical suturesSuture TechniquesTechniquesTechnologyTendon InjuriesTendon structureTestingTissue EngineeringTissue GraftsTissuesToxicologyTranslationsUnited StatesVisionWomanWorkaging populationanterior cruciate ligament injurybiological developmentbiomaterial compatibilitybonebone marrow mesenchymal stem cellcell bankcommercializationcostdesignfabricationfirst-in-humanhealinghumerusimprovedin vivoinnovationlaboratory equipmentmanufacturemechanical signalmigrationmineralizationnovelprotein structurerepair strategyrepairedrestorationrotator cuff injuryrotator cuff tearsafety testingscaffoldskeletal tissuesoft tissuestandard of caresuccesssurgery outcometendon grafttissue regeneration
项目摘要
PROJECT SUMMARY/ABSTRACT
Introduction: Skeletal Tissue Engineering Laboratories (STEL) Technologies, LLC is a woman-owned, Michigan-
based regenerative medicine company founded in 2013. STEL’s first product, the CGEMTM graft, is a unique
biological replacement for the anterior cruciate ligament (ACL) injuries. The researchers have since adapted this
graft technology with the goal of treating Rotator Cuff (RC) injuries increasingly prevalent in the aging population.
Significance: RC tears are a major orthopedic challenge in the US with over 460,000 surgeries performed
annually resulting in a market cost of over $523M[1,46]. The failure rate of current RC repair procedures ranges
from 20-95%, with a major contributing factor being the inability to restore native biomechanical properties at the
enthesis, resulting in repairs characterized by a weaker, less organized fibrovascular scar tissue that is prone to
failure[54]. Various tissue-engineering strategies are being developed to improve surgical outcomes and promote
tendon healing, especially at the enthesis. Current approaches focus on the development of biological or
synthetic scaffold devices to reinforce the mechanical strength of the tendon-to-bone connection, but they do not
promote enthesis regeneration. There is significant demand for alternative technologies for RC repair.
Vision for Commercial Product: The ETG-RC is devitalized allogeneic engineered multi-phasic tissue that
regenerates the enthesis and provide an underlayment that allows the migration of endogenous cells, enhancing
the regenerative capacity of the repair site. ETG-RC will lead to enhanced restoration of normal biomechanics
and mobility, resulting in lower cost and decreased risk of re-injury and arthritis. An “off-the-shelf” tissue graft for
RC repair will enhance the standard of care double row suture technique and deliver superior patient outcomes.
Goals of Proposed Research: The goals of this SBIR Project are to establish the feasibility of fabricating a fully
biologic “off-the-shelf” tissue-engineered rotator cuff tendon graft that can restore biomechanical properties of
the tendon-humerus enthesis; and to de-risk the commercial viability of ETG-RC in order to advance the
translatability of this technology for use in human patients.
Specific Aims: The proposed project addresses the several pressing issues that must be resolved prior to
bringing this technology to the FDA for clinical trials: development of a fabrication and decellularization protocol
(Aim 1) and establishment of storage methods to determine shelf life (Aim 2). It then seeks to establish a master
cell bank for fabrication of grafts for the Phase 1-3 clinical trials (Aim 3). CGMP quality ETG-RC grafts fabricated
from the established master cell bank will be tested for safety and efficacy by NAMSA (Aim 4). Positive data
from these studies will support filing of an IND-packet with FDA, enabling a Phase I clinical trial. Success of the
SBIR project will result in the development of an “off-the-shelf” tendon graft ready for first-in-human Phase I
clinical trials. This represents a significant commercialization milestone and a transformative innovation for the
treatment of soft tissue orthopedic injuries.
项目总结/摘要
简介:Skeleton组织工程实验室(STEL)技术有限责任公司是一家女性拥有的密歇根州-
再生医学公司成立于2013年。STEL的第一个产品CGEM ™移植物是一种独特的
前交叉韧带(ACL)损伤的生物替代。研究人员已经对此进行了调整,
移植技术的目的是治疗肩袖(RC)损伤日益普遍的老龄人口。
意义:在美国,RC撕裂是一个主要的骨科挑战,进行了超过460,000例手术
每年的市场成本超过5.23亿美元[1,46]。目前钢筋混凝土修复程序的失败率范围
从20- 95%,一个主要的影响因素是无法恢复天然的生物力学性能,
附着点,导致修复,其特征在于更弱,组织更少的纤维血管瘢痕组织,
失败[54]。正在开发各种组织工程策略以改善手术结果并促进
肌腱愈合,特别是在附着点。目前的方法侧重于开发生物或
合成支架装置,以加强肌腱-骨连接的机械强度,但它们不
促进附着点再生。对钢筋混凝土维修的替代技术有很大的需求。
商业产品愿景:ETG-RC是灭活同种异体工程化多相组织,
再生附着点并提供允许内源性细胞迁移的基底,
修复部位的再生能力。ETG-RC将增强正常生物力学的恢复
和灵活性,从而降低成本并降低再次受伤和关节炎的风险。一种“现成的”组织移植物,
RC修复将提高双排缝合技术的护理标准,并提供上级患者结局。
建议的研究目标:这个SBIR项目的目标是建立一个完整的制造的可行性,
生物“现成的”组织工程肩袖肌腱移植物,可以恢复生物力学性能,
肌腱-肱骨附着点;并降低ETG-RC的商业可行性风险,以促进
该技术用于人类患者的可转化性。
具体目标:拟议的项目解决了几个紧迫的问题,必须解决之前,
将这项技术提交给FDA进行临床试验:开发制造和脱细胞方案
(Aim 1)和建立储存方法,以确定有效期(目的2)。然后,它试图建立一个主
用于制造1-3期临床试验(Aim 3)移植物的细胞库。制造CGMP质量ETG-RC移植物
将由NAMSA对已建立的主细胞库中的细胞进行安全性和有效性试验(目标4)。正数据
这些研究将支持向FDA提交IND数据包,从而能够进行I期临床试验。成功
SBIR项目将导致开发一种“现成的”肌腱移植物,用于第一次人体I期试验
临床试验这是一个重要的商业化里程碑,也是
治疗软组织骨科损伤。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Thomas Bollenbach其他文献
Thomas Bollenbach的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Thomas Bollenbach', 18)}}的其他基金
TR&D-4: Growing Tissue in the Scalable, Modular, Automated, and Closed (SMAC) Foundry
TR
- 批准号:
10554853 - 财政年份:2016
- 资助金额:
$ 94.33万 - 项目类别:
相似海外基金
HLA-homozygous iPSC-cardiomyocytE Aggregate manufacturing technoLogies for allogenic cell therapy to the heart (HEAL)
HLA-纯合 iPSC-心肌细胞 用于心脏同种异体细胞治疗 (HEAL) 的聚集体制造技术
- 批准号:
10039902 - 财政年份:2022
- 资助金额:
$ 94.33万 - 项目类别:
EU-Funded
Evaluation of the efficacy of LAT1 inhibitor to tumor stroma and immunity in an allogenic mouse model of colon cancer having abundant stroma.
在具有丰富基质的同种异体结肠癌小鼠模型中评估 LAT1 抑制剂对肿瘤基质和免疫的功效。
- 批准号:
21K15925 - 财政年份:2021
- 资助金额:
$ 94.33万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Mechanism of kidney injury associated with graft-versus-host disease after allogenic stem cell transplantation
同种异体干细胞移植后移植物抗宿主病相关肾损伤的机制
- 批准号:
21K08410 - 财政年份:2021
- 资助金额:
$ 94.33万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Clarification of the origin and maintenance mechanisms of junctional epithelium and identification of its stem cells using allogenic tooth germ transplantation
阐明交界上皮的起源和维持机制并利用同种异体牙胚移植鉴定其干细胞
- 批准号:
20K21672 - 财政年份:2020
- 资助金额:
$ 94.33万 - 项目类别:
Grant-in-Aid for Challenging Research (Exploratory)
The study about the allogenic MSCs transplantation to the cardiac disease models.
同种异体间充质干细胞移植至心脏病模型的研究。
- 批准号:
18K16395 - 财政年份:2018
- 资助金额:
$ 94.33万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Artificial nerves containing allogenic basal lamellae scaffold and bone marrow derived stem cells
含有同种异体基底板层支架和骨髓干细胞的人工神经
- 批准号:
17K10951 - 财政年份:2017
- 资助金额:
$ 94.33万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Role of HSP90-alpha in preserving immunoprivilege of allogenic mesenchymal stem cells in the ischemic heart
HSP90-α 在保护缺血心脏同种异体间充质干细胞免疫特权中的作用
- 批准号:
370541 - 财政年份:2017
- 资助金额:
$ 94.33万 - 项目类别:
Operating Grants
Attempt to Prefabricate Vascularized Allogenic Bone in Recipient -Use of Cultured Bone Marrow Cells-
尝试在受者体内预制血管化的同种异体骨 - 使用培养的骨髓细胞 -
- 批准号:
16K10863 - 财政年份:2016
- 资助金额:
$ 94.33万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Allogenic micobiota-reconstitution (AMR) for the treatment of patients with diarhea-predominant irritable bowel syndrome (IBS-D) - the AMIRA trial
同种异体微生物群重建 (AMR) 用于治疗腹泻型肠易激综合征 (IBS-D) 患者 - AMIRA 试验
- 批准号:
276706135 - 财政年份:2015
- 资助金额:
$ 94.33万 - 项目类别:
Clinical Trials
Induction of thyme epithelial cells from iPS cells and application to allogenic transplantation
iPS细胞诱导百里香上皮细胞及其在同种异体移植中的应用
- 批准号:
15H04915 - 财政年份:2015
- 资助金额:
$ 94.33万 - 项目类别:
Grant-in-Aid for Scientific Research (B)